Brief: Cogent Biosciences Announces Positive FDA Meeting And Alignment On MS2D2

Cogent Biosciences

27/06/2024 13:39

June 27 (Reuters) - Cogent Biosciences Inc  COGT.O :
    * COGENT BIOSCIENCES ANNOUNCES POSITIVE FDA MEETING AND
ALIGNMENT
ON MS2D2, A NOVEL PATIENT REPORTED OUTCOME MEASURE FOR THE
SUMMIT TRIAL
    * COGENT BIOSCIENCES INC: REMAIN ON TRACK TO COMPLETE
ENROLLMENT
IN SUMMIT PART 2 IN Q2 OF 2025 AND REPORT TOP-LINE RESULTS BY
YEAR-END 2025
    * COGENT BIOSCIENCES ANNOUNCES POSITIVE FDA MEETING AND
ALIGNMENT
ON MS2D2, A NOVEL PATIENT REPORTED OUTCOME MEASURE FOR THE
SUMMIT TRIAL

Source text for Eikon:  ID:nGNX51mz91 
Further company coverage:  COGT.O 

 ((Reuters.Briefs@thomsonreuters.com;))